Return to search results
Omalizumab
Xolair (omalizumab) is a prescription medication made by Genentech, Inc., used to treat allergic asthma and chronic hives by blocking IgE antibodies that trigger allergic reactions. It's administered as a subcutaneous injection in vials or prefilled syringes with strengths like 75 mg, 150 mg, or 300 mg. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Xolair (omalizumab) is a prescription medication made by Genentech, Inc., used to treat allergic asthma and chronic hives by blocking IgE antibodies that trigger allergic reactions. It's administered as a subcutaneous injection in vials or prefilled syringes with strengths like 75 mg, 150 mg, or 300 mg. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Omalizumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Omalizumab — ANDA 103976 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976"
}
]
|
| identifier | ANDA103976 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-manufacturers",
"fda",
"medications"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Omalizumab |
